You are here: Home » PTI Stories » National » News
Business Standard

Granules gets USFDA nod for postpartum haemorrhage prevention drug

Press Trust of India  |  New Delhi 

Drug firm Granules India today said its subsidiary has received approval from the US regulator for tablets, used for the prevention and control of postpartum haemorrhage.

In a filing to BSE, Granules India said "the U S (USFDA) has approved its (ANDA) for 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India Ltd".

The approved product is the bioequivalent to the reference listed drug product 0.2 mg, it added.

Shares of Granules India were trading at Rs 105.40 per scrip on BSE, up 8.94 per cent.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, May 17 2018. 10:55 IST